Abstract:Tumor is one of the most serious threats for human being. Although many anti-tumor drugs are approved for clinical use, the treatment outcome is still modest because of the poor tumor targeting efficiency and low accumulation in tumor. Therefore, it is important to deliver anti-tumor drug into tumor efficiently, elevate drug concentration in tumor tissues and reduce the drug distribution in normal tissues. And it has been one of the most attractive directions of pharmaceutical academy and industry. Many kinds of strategies, especially various nanoparticulated drug delivery systems, have been developed to address the critical points of complex tumor microenvironment, which are partially or mostly satisfied for tumor treatment. In this paper, we carefully reviewed the novel targeting delivery strategies developed in recent years. The most powerful method is passive targeting delivery based on the enhanced permeability and retention(EPR) effect, and most commercial nanomedicines are based on the EPR effect. However, the high permeability and retention require different particle sizes, thus several kinds of size-changeable nanoparticles are developed, such as size reducible particles and assemble particles, to satisfy the controversial requirement for particle size and enhance both tumor retention and penetration. Surface charge reversible nanoparticles also shows a high efficiency because the anionic charge in blood circulation and normal organs decrease the unintended internalization. The charge can change into positive in tumor microenvironment, facilitating drug uptake by tumor cells. Additionally, tumor microenvironment responsive drug release is important to decrease drug side effect, and many strategies are developed, such as p H sensitive release and enzyme sensitive release. Except the responsive nanoparticles, shaping tumor microenvironment could attenuate the barriers in drug delivery, for example, decreasing tumor collagen intensity and normalizing tumor microvessels to decrease the internal fluid pressure. All these strategies could enhance the accumulation and penetration of nanoparticles into tumor, leading to a homogenous distribution of drugs in tumor. To enhance the internalization by specific cells, active targeting delivery strategies are developed. There were many surface markers, receptors or carriers overexpressed on specific kinds of cells, thus the corresponding ligands were utilized to mediate active targeting to certain cells, including tumor cells, cancer stem cells, tumor neovasculatures, tumor associated macrophages and other tumor stroma cells. Targeting more than one cell type may provide an improved antitumor effect. Although these passive and active targeting strategies all have promising outcome in the treatment of tumor, some shortages are still unaddressed, such as the specificity of responsive is not good enough, and the active targeting may be diminished by the protein corona. Thus more research is required to promote the drug delivery study.

Advancement on Targeting Therapy of Tumor Vessels

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Antibody-directed Targeting of Tumor Vasculature

Recent advances of nanotechnology-based tumor vessel-targeting strategies

Advance in Gene Therapy of Tumors

Advances in tumor vascular growth inhibition

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Research Progress on Tumor-Targeting Immunoconjugate

Antiangiogenic therapy: how far is it to upgrade?

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Research Advance in Vascular Endothelial Growth Factor and Anti-Tumor

Advances in Anti-Tumor Therapy Targeting the EGFR Family of Receptor Tyrosine Kinases

Targeting the tumour vasculature: from vessel destruction to promotion

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems

Anti-angiogenic Therapy for Tumor: Tumor Angiogenesis, Vasculogenic Mimicry and Vascular Normalization

Progress in Anti-Angiogenesis Targeted Drugs

Targeting angiogenesis in oncology, ophthalmology and beyond

[The Development of Novel Tumor Targeting Delivery Strategy].

Research status of anti-tumor targted drugs